Workflow
Strength Seen in CareDx (CDNA): Can Its 6.1% Jump Turn into More Strength?
CDNACareDx(CDNA) ZACKS·2025-01-14 09:50

Core Insights - CareDx (CDNA) shares increased by 6.1% to close at 25.07,attributedtohighertradingvolumecomparedtotypicalsessions,witha3.425.07, attributed to higher trading volume compared to typical sessions, with a 3.4% gain over the past four weeks [1] Financial Performance - CareDx is expected to report preliminary fourth-quarter 2024 revenues between 85 million and 86million,reflectinga3086 million, reflecting a 30% year-over-year increase, surpassing the Zacks Consensus Estimate of 25.2% growth [2] - Testing service revenue is projected to rise nearly 35% year-over-year, driven by a 14% increase in volumes [2] - The company anticipates quarterly earnings of 0.07 per share, representing a year-over-year increase of 141.2%, with revenues expected to reach $82.12 million, up 25.2% from the previous year [3] Earnings Estimates and Stock Performance - The consensus EPS estimate for CareDx has remained unchanged over the last 30 days, indicating that stock price movements may not sustain without trends in earnings estimate revisions [4] - CareDx currently holds a Zacks Rank of 3 (Hold), while another company in the medical services industry, Avantor, Inc. (AVTR), has a Zacks Rank of 4 (Sell) [4]